HIV / AIDS

Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.

Modulating gut microbiota could have therapeutic benefits for people living with HIV, according to a recent study that found HIV infection in women was associated with altered gut microbiota and distinct plasma metabolite profile.

New data sheds light on efficacy of longer periods between dosing.

Antiviral therapy that suppresses HIV-1 viremia does not block release of cell-associated RNA after infection or the inflammatory response it provokes.

The HIV Policy Lab report examined which countries are adopting laws endorsed by various international agencies in the fight against AIDS.

The Aptima HIV-1 Quant Dx assay is the first in the US to be able to make such a claim.

Researchers have identified the Ski complex as a promising target for antiviral drugs in the fight against coronaviruses.

Gilead has announced that its investigational long-acting HIV-1 capsid inhibitor, lenacapavir, has achieved its primary endpoint in a phase 2/3 CAPELLA trial.

The US Food and Drug Administration has granted breakthrough therapy designation for an investigational drug, a long-acting, injectable cabotegravir for HIV pre-exposure-prophylaxis (PrEP).

HIV care has made leaps and bounds over the past few years. New guidance for primary care physicians addresses these changes and acknowledges the diversity and complexity of individuals with HIV.

The authors also addressed how HIV may interact with the coronavirus.

When administered every two months, cabotegravir is 89% more effective than daily pills in preventing HIV acquisition in women.

Investigators found these populations are younger and are living at or below poverty were at lower adherence to ART.

New 96-week data show dolutegravir-based regimens are non-inferior to efavirenz-based regimens, but the data also raise concerns about excessive weight gain.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

A cross-specialty collaboration to mitigate inpatient cases of opioid use disorder has had early success; developers want to grow it.

A firsthand look into a Kentucky program that's initiated opioid use disorder care in recurring HIV, hepatitis C patients.

Investigators wanted to look at real world experiences with combination therapy in older people living with HIV.

Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.

The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.

A study looked at weight gain when changing therapy regimens.

Improving clinical care and outcomes among those with and at risk for HIV was the target for updating the antiretroviral treatment regimen recommendations.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.